Pharmacology of a new orally active antiallergic

Pyrido[1,2-a]pyrimidine, ucb L140 (CHINOIN 1045) in rats

C. de Vos, F. Dessy, I. Hermecz, Z. Meszaros, T. Breining

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

ucb L140 (CHINOIN 1045) has been tested in various rat anaphylaxis systems. In models of passive cutaneous anaphylaxis (PCA), passive peritoneal anaphylaxis (PPA) and anaphylactic bronchospasms, ucb L140 appears to be more potent than sodium cromoglycate (DSCG). Upon oral administration, ucb L140 exhibits a marked inhibition of these anaphlactic reaction. Sensitized rat mast cells in vitro display a decreased Nippostrongylus-induced histamine release when treated with a concentration of ucb L140 three times smaller than DSCG. In PCA testing after intravenous administration of ucb L140 a cross-tachyphylaxis with DSCG was observed. These results suggest that the action of ucb L140 is similar to that of DSCG in inhibiting the release of allergic mediators from mast cells and therefore may present antiallergic activity.

Original languageEnglish
Pages (from-to)362-368
Number of pages7
JournalInternational Archives of Allergy and Applied Immunology
Volume67
Issue number4
Publication statusPublished - 1982

Fingerprint

Anti-Allergic Agents
Pharmacology
Passive Cutaneous Anaphylaxis
Anaphylaxis
Mast Cells
Nippostrongylus
Tachyphylaxis
Cromolyn Sodium
Bronchial Spasm
Histamine Release
pyrimidine
ucb L140
Intravenous Administration
Oral Administration

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Pharmacology of a new orally active antiallergic : Pyrido[1,2-a]pyrimidine, ucb L140 (CHINOIN 1045) in rats. / de Vos, C.; Dessy, F.; Hermecz, I.; Meszaros, Z.; Breining, T.

In: International Archives of Allergy and Applied Immunology, Vol. 67, No. 4, 1982, p. 362-368.

Research output: Contribution to journalArticle

@article{de95cc1d83a948a599d33f9fc7e51188,
title = "Pharmacology of a new orally active antiallergic: Pyrido[1,2-a]pyrimidine, ucb L140 (CHINOIN 1045) in rats",
abstract = "ucb L140 (CHINOIN 1045) has been tested in various rat anaphylaxis systems. In models of passive cutaneous anaphylaxis (PCA), passive peritoneal anaphylaxis (PPA) and anaphylactic bronchospasms, ucb L140 appears to be more potent than sodium cromoglycate (DSCG). Upon oral administration, ucb L140 exhibits a marked inhibition of these anaphlactic reaction. Sensitized rat mast cells in vitro display a decreased Nippostrongylus-induced histamine release when treated with a concentration of ucb L140 three times smaller than DSCG. In PCA testing after intravenous administration of ucb L140 a cross-tachyphylaxis with DSCG was observed. These results suggest that the action of ucb L140 is similar to that of DSCG in inhibiting the release of allergic mediators from mast cells and therefore may present antiallergic activity.",
author = "{de Vos}, C. and F. Dessy and I. Hermecz and Z. Meszaros and T. Breining",
year = "1982",
language = "English",
volume = "67",
pages = "362--368",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Pharmacology of a new orally active antiallergic

T2 - Pyrido[1,2-a]pyrimidine, ucb L140 (CHINOIN 1045) in rats

AU - de Vos, C.

AU - Dessy, F.

AU - Hermecz, I.

AU - Meszaros, Z.

AU - Breining, T.

PY - 1982

Y1 - 1982

N2 - ucb L140 (CHINOIN 1045) has been tested in various rat anaphylaxis systems. In models of passive cutaneous anaphylaxis (PCA), passive peritoneal anaphylaxis (PPA) and anaphylactic bronchospasms, ucb L140 appears to be more potent than sodium cromoglycate (DSCG). Upon oral administration, ucb L140 exhibits a marked inhibition of these anaphlactic reaction. Sensitized rat mast cells in vitro display a decreased Nippostrongylus-induced histamine release when treated with a concentration of ucb L140 three times smaller than DSCG. In PCA testing after intravenous administration of ucb L140 a cross-tachyphylaxis with DSCG was observed. These results suggest that the action of ucb L140 is similar to that of DSCG in inhibiting the release of allergic mediators from mast cells and therefore may present antiallergic activity.

AB - ucb L140 (CHINOIN 1045) has been tested in various rat anaphylaxis systems. In models of passive cutaneous anaphylaxis (PCA), passive peritoneal anaphylaxis (PPA) and anaphylactic bronchospasms, ucb L140 appears to be more potent than sodium cromoglycate (DSCG). Upon oral administration, ucb L140 exhibits a marked inhibition of these anaphlactic reaction. Sensitized rat mast cells in vitro display a decreased Nippostrongylus-induced histamine release when treated with a concentration of ucb L140 three times smaller than DSCG. In PCA testing after intravenous administration of ucb L140 a cross-tachyphylaxis with DSCG was observed. These results suggest that the action of ucb L140 is similar to that of DSCG in inhibiting the release of allergic mediators from mast cells and therefore may present antiallergic activity.

UR - http://www.scopus.com/inward/record.url?scp=0020049165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020049165&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 362

EP - 368

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 4

ER -